HAEMATOLOGICAL PREDICTORS OF THE ACUTE COURSE OF ANEURYSMAL SUBARACHNOID HAEMORRHAGE
Acta Medica Leopoliensia · 22.12.2025 · 31 (3-4) · 9-25
DOI: 10.25040/aml2025.3-4.009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Medica Leopoliensia, online erschienen am 22.12.2025. Verfasst von Yuliia Solodovnikova und 2 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Anaemia affects nearly half of patients with aneurysmal subarachnoid haemorrhage (aSAH). Low haemoglobin (Hb) level is associated with more severe clinical conditions and poorer outcomes. Reducing haematocrit (Hct) has historically been used in Triple-H therapy, although its effect on cerebral perfusion remains unclear. Aim. To assess Hb, Hct, and the Hb/Hct ratio in association with clinical features, treatment, complications, and outcomes after aSAH. Material and Methods. This study included 492 medical records of patients with aSAH. The dataset included demographic and clinical characteristics, haematological parameters, cerebral aneurysm features, treatment methods, complications, and outcomes. Results and Discussion. Each one-unit increase in Hb and Hct reduced the probability of pneumonia by 19.1% (P
Zitieren
APA
Solodovnikova, Y., Revurko, A., & Son, A. (2025). HAEMATOLOGICAL PREDICTORS OF THE ACUTE COURSE OF ANEURYSMAL SUBARACHNOID HAEMORRHAGE. Acta Medica Leopoliensia, 31(3-4), 9-25. https://doi.org/10.25040/aml2025.3-4.009
Vancouver
Solodovnikova Y, Revurko A, Son A. HAEMATOLOGICAL PREDICTORS OF THE ACUTE COURSE OF ANEURYSMAL SUBARACHNOID HAEMORRHAGE. Acta Medica Leopoliensia. 2025;31(3-4):9-25. doi:10.25040/aml2025.3-4.009
BibTeX
@article{Solodovnikova2025,
author = {Solodovnikova, Yuliia and Revurko, Anastasiia and Son, Anatoliy},
title = {HAEMATOLOGICAL PREDICTORS OF THE ACUTE COURSE OF ANEURYSMAL SUBARACHNOID HAEMORRHAGE},
journal = {Acta Medica Leopoliensia},
year = {2025},
volume = {31},
number = {3-4},
pages = {9--25},
doi = {10.25040/aml2025.3-4.009}
}
EUVIMED